ANIP
ANI Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
动量输入(同类管理人):
持有人广度 -25.0% ·
股份流向 +30.0% ·
净新建仓位 -20.0%
· 公式
集中增持:持股数量上升,持有人数量减少
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q3 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 15.90K | $1.15M | n/a | n/a |
| Q2 2026 | 100 | +1 | 15.23M | $1.21B | +7 | −7 |
| Q1 2026 | 103 | -4 | 30.24M | $1.11B | +4 | −9 |
| Q4 2025 | 108 | 0 | 15.43M | $1.15B | +1 | n/a |
| Q3 2025 | 20 | +5 | 7.92M | $725.10M | +5 | −1 |
| Q2 2025 | 13 | -1 | 6.82M | $445.05M | n/a | −1 |
| Q1 2025 | 11 | +3 | 3.19M | $213.52M | +3 | n/a |
| Q4 2024 | 8 | -2 | 3.16M | $174.48M | n/a | −2 |
| Q3 2024 | 9 | -3 | 1.88M | $111.88M | n/a | −3 |
| Q2 2024 | 12 | n/a | 1.26M | $80.52M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 529.88K | +43.9% | $31.61M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 529.75K | +130.2% | $31.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 425.23K | +4.2% | $25.37M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Renaissance Technologies ✦ | 245.10K | +56.3% | $14.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 108.62K | +1140.0% | $6.48M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 15.40K | -12.1% | $919,003 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 9.41K | -78.4% | $561,461 | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 8 | T. Rowe Price ✦ | 6.07K | +3.2% | $363,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 5.71K | -21.9% | $340,420 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Arrowstreet Capital | $592,000 | 曾为 0.0% |
| Gotham Asset Management | $313,879 | 曾为 0.0% |
| Marshall Wace | $253,383 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 4 持有人, 27.49M 股份, $50.55M 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director · 5.40K 股 · $388,206
Officer · 500 股 · $36,795
Officer · 2.85K 股 · $208,050
Officer, Director · 5.40K 股 · $383,400
Officer · 500 股 · $35,395
Director · 1.00K 股 · $71,530
Officer · 2.85K 股 · $207,480
Officer, Director · 5.40K 股 · $401,220
Officer · 500 股 · $37,740
Officer · 3.16K 股 · $243,474
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论